Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki
PARIS, May 18 /PRNewswire/ -- Novexel, a speciality pharmaceutical
company focused on the discovery and development of novel antibiotics
designed to overcome the significant global problem of microbial resistance,
announces that its two most advanced pipeline products NXL104 and NXL103 are
Progress Against Malaria and Other Infectious Diseases Among Highlights at Annual Vaccine Conference
BALTIMORE, April 27 /PRNewswire/ -- Global progress toward a malaria vaccine is among the key topics to be presented at the 12th Annual Conference on Vaccine Research (ACVR), sponsored by the National Foundation for Infectious Diseases
(NFID) April 27-29, 2009 in Baltimore. The ACVR is the world's...
Infant Blood May Provide Insights into Diseases Present at Birth
GRAND RAPIDS, Mich., Dec. 15 /PRNewswire/ -- Van Andel Institute (VAI)
researchers are the first to apply a new technology to measure on a large
scale the presence of genes in blood spots - the blood drawn from newborn
infants to screen for health-threatening conditions. Using a random sample of
First Clinical Experience With Soliris(R) in Treating Patients With Two Rare Complement-Mediated Diseases Presented at ASH Annual Meeting
CHESHIRE, Conn., Dec. 7 /PRNewswire-FirstCall/-- Soliris(R) (eculizumab),
a terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc.
(Nasdaq: ALXN ) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH),
was associated with an improvement in hematologic parameters in a l...
Rapid Test for Pathogens Developed By K-State Researchers Could Be Used to Detect Diseases Used By Bioterrorists
MANHATTAN, Kan., Aug. 21 /PRNewswire-USNewswire/ -- Dangerous disease
often spreads faster than it takes to diagnose it in the lab. To remedy
that, researchers at Kansas State University have developed a test to bring
that time from days down to hours.
Sanjeev Narayanan, assistant professor,...
Bristol-Myers Squibb, New Jersey Children's Hospital Launch Center for Immune System Disorders & Infectious Diseases Including HIV/AIDS
NEW BRUNSWICK, N.J., Nov. 30 /PRNewswire-FirstCall/ -- Underscoring its
worldwide commitment to children with HIV/AIDS, Bristol-Myers Squibb
Company (NYSE: BMY ) today joined Robert Wood Johnson University Hospital in
opening a new clinical center at The Bristol-Myers Squibb Children's
Lack of Medicare Part D Coverage for All Medically Necessary Prescriptions Endangers Older Americans and Those with Chronic Diseases and Disabilities
Coalition of Patient and Consumer Groups calls for Legislative Action to Ensure Access to 'Off-Label' Drug Treatments
WASHINGTON, Nov. 20 /PRNewswire-USNewswire/ -- Twenty-six patient,
family caregiver and health professional organizations are calling upon
Congress to pass legisla...
Vital Therapies Announces Presentation of ELAD(R) 'Artificial Liver' Data at American Association for the Study of Liver Diseases 2007 Annual Meeting
BOSTON, Nov. 7 /PRNewswire/ -- Vital Therapies, Inc. (VTI), announced
today data from two studies of the company's ELAD(R) (Extracorporeal Liver
Assist Device) System were presented at the 2007 American Association for
the Study of Liver Diseases
(AASLD) Annual Meeting, which was held November...
Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
KENILWORTH, N.J., Oct. 30 /PRNewswire-FirstCall/ -- Leading researchers
will present 68 data presentations involving Schering-Plough's hepatitis
products, including PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R)
(ribavirin, USP) combination therapy, a current standard of care in the
Tiny Cup Attached to Eye Improves Drug Delivery For Retinal Diseases
LOS ANGELES, Aug. 7 /PRNewswire-USNewswire/ -- A new drug delivery system that uses a tiny silicone cup filled with any drug and sealed to the outer surface (episclera) of the eyeball may offer a more effective method for the sustained delivery of medicines for retinal and vitreous disea...
Mayo Clinic Proceedings Reviews Deep Brain Stimulation to Treat Psychiatric Diseases
ROCHESTER, Minn., June 29 /PRNewswire-USNewswire/ -- Pioneering therapeutic trials to investigate the effectiveness of deep brain stimulation (DBS) in hard-to-treat depression, obsessive-compulsive disorder (OCD) and Tourette's syndrome are underway at multiple medical centers around the worl...
ALP Life Sciences, LLC Announces Nanoveson(TM) Patent Filing and Whitepaper Availability on Proposed Therapy for Non-Alcoholic Fatty Liver Disease (NAFLD) and Comorbid Diseases
BLACK MOUNTAIN, N.C., June 24 /PRNewswire/ -- ALP Life Sciences, LLC (Company) today announced the Nanoveson(TM) patent has been filed and the Nanoveson(TM) whitepaper is available at www.ALPLifeSciences.com/wp . After completing initial research, the Company is pursuing clinical trials an...
New Legislation Seeks to Boost Participation in Clinical Trials for Rare Diseases
Bill would remove financial penalties for participating in research studies
BETHESDA, Md., June 15 /PRNewswire-USNewswire/ -- New legislation introduced today would allow patients with rare diseases
to participate in clinical drug studies without losing their eligibility for government health...
Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
Clinical results and advantage over linezolid in resistance acquisition by Staph aureus among data to be presented at infectious disease meeting
SAN DIEGO, Calif., May 6 /PRNewswire/ -- Trius Therapeutics, Inc., a biopharmaceutical company developing best-in-class drugs for the treatment of s...
Lions Eye Institute for Transplant & Research, Inc. Launches Multi-Million Dollar, State-of-the-Art Research Institute that Will Advance the Study of Blinding Eye Diseases
TAMPA, Fla., May 5 /PRNewswire-USNewswire/ -- The Tampa Lions Eye Institute for Transplant and Research, Inc. (LEITR) today announced plans to open a new 12,000-square-foot facility in Tampa, Florida. This state-of-the-art facility will offer high-volume, high-quality human ocular tissue for resea...
Study Shows How Defective DNA Repair Triggers Two Neurological Diseases
St. Jude scientists' findings in ataxia telangiectasia-like disease and Nijmegen breakage syndrome offer insight into the links between brain disease and cancer vulnerability in people carrying the diseases
MEMPHIS, Tenn., Jan. 14 /PRNewswire-USNewswire/ -- Scientists at St. Jude Children's...
42 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases
LANSDOWNE, Va., Nov. 18 /PRNewswire-USNewswire/ -- Forty-two leading U. S. scientists and specialists gathered at a November national forum to consider cutting-edge innovations that may defend America's public health and national economy from outbreaks of dangerous zoonotic diseases, the FAZD Cent...
ImmunoVaccine Technologies' DepoVax(TM) Shows Positive Results for Cancer and Infectious Diseases
HALIFAX, Oct. 1 /PRNewswire/ - ImmunoVaccine Technologies' (IVT)
patented depot vaccine formulation, DepoVax(TM) is showing positive
pre-clinical results, with single-dose efficacy achieved in therapeutic
cancer and several infectious disease vaccine models. The results of this
research will b...
SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
SOUTH SAN FRANCISCO, Calif., Sept. 5 /PRNewswire-FirstCall/ -- SARcode
Corporation, a private company focused on small molecule LFA-1 inhibitors
to treat inflammatory diseases, and Sunesis Pharmaceuticals, Inc. (Nasdaq:
SNSS) today announced SARcode's initiation of a Phase 1 clinical trial of ...
Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
EAST SETAUKET, N.Y., Aug. 12 /PRNewswire-FirstCall/ -- Lixte
Biotechnology Holdings, Inc. (OTC Bulletin Board: LIXT) announced today
that it had filed a patent application for the use of compounds the company
is developing for treatment of brain tumors as potential treatments for
Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
Partners Expect Program to Advance to the Clinic Within a Year; Studies Generate Milestone Payment to Micromet
BETHESDA, Md., and ZURICH, Switzerland, June 24 /PRNewswire/ --
Micromet, Inc. (Nasdaq: MITI ) and Nycomed today announced the initiation of
formal preclinical safety...
Foamix and Galderma to Develop Medicated Foam for Certain Skin Diseases
NESS ZIONA, Israel and SOPHIA-ANTIPOLIS, France, April 29 /PRNewswire/
-- Foamix Ltd, a global leader in the development of dermatological foam
medications and Galderma, a worldwide specialty pharmaceutical company
focused on dermatology, today announced that they have signed an agreement
Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
SAN DIEGO and SUNNYVALE, Calif., April 14 /PRNewswire-FirstCall/ --
Pharmacyclics, Inc. (Nasdaq: PCYC ) today presented results from its
preclinical program evaluating PCI-32765, an orally available, selective
inhibitor of Bruton's tyrosine kinase, or Btk, in B-cell receptor (BCR)
deCODE Obesity Study Sheds Light on How Genetics Affects Risk and Onset of Common Diseases
REYKJAVIK, Iceland, March 16 /PRNewswire-FirstCall/ -- In a paper
published online today in the journal Nature, a team of deCODE scientists
detail a major mechanism through which genetic factors contribute to major
public health problems. In its work on the inherited components of dozens
St. Jude Finds Molecule That Could Improve Cancer Vaccine and Therapy for Other Diseases
The discovery of a new cytokine called IL-35 could allow clinicians to
by turning up or down the immune response
MEMPHIS, Tenn., Nov. 21 /PRNewswire-USNewswire/ -- Investigators at St.
Jude Children's Research Hospital have discovered a new signaling molecule
that prevents i...
Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
Safety Analysis Shows Good Tolerance with No Serious Adverse Reactions
BERKELEY HEIGHTS, N.J., Nov. 15 /PRNewswire-FirstCall/ -- Genta
Incorporated (Nasdaq: GNTA ) released findings from the initial clinical
dosing of G4544, the Company's proprietary small molecule that is intended
as a trea...
Pharmaceutical Companies Lead Fight Against Staph and Other Infectious Diseases
WASHINGTON, Nov. 6 /PRNewswire-USNewswire/ -- A new report released
today by the Pharmaceutical Research and Manufacturers of America (PhRMA)
finds that America's pharmaceutical research companies are now testing 338
new medicines to help treat infectious diseases, including 11 medicines and
Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
BRISBANE, Australia, Nov. 5 /PRNewswire-FirstCall/ -- Progen
Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today announced additional
data from the Phase 2 liver cancer study of PI-88 completed earlier this
year. This data was presented at the 58th Annual Meeting of the American
SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
SAN DIEGO and MCLEAN, Va., Nov. 1 /PRNewswire-FirstCall/ -- Science
Applications International Corporation (NYSE: SAI ) today announced that it
was awarded a contract extension by the National Institute of Allergy and
Infectious Diseases' (NIAID) Division of Microbiology and Infectious
EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimer's, Schizophrenia and Huntington's Diseases
WATERTOWN, Mass., Oct. 17 /PRNewswire/ -- EnVivo Pharmaceuticals, Inc.,
a privately held biopharmaceutical company developing drugs for
neurodegenerative diseases, today announced progress on several key
programs for addressing Alzheimer's, Schizophrenia and Huntington's
diseases. EnVivo Phar...
Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
-Acquisition of Pacific Pharma Technologies Brings Proprietary Artificial
Intelligence-Based Drug Discovery Platform and Novel Drug Candidates to Upstream- -Initial Compounds Demonstrate Promising In Vitro Activity Against
Devastating Parasitic Diseases
Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
PALO ALTO, Calif., Aug. 24 /PRNewswire-FirstCall/ -- Avicena Group,
Inc. (OTC Bulletin Board: AVGO), a late stage biotechnology company that
develops central nervous system therapeutics for neurodegenerative
diseases, announced today that Mark A. Tarnopolsky, MD, PhD, FRCPC,
professor at McMas...
Second Successful Quigley QR-443 Study Suggests Method of Action
Relevant to Broad Range of Chronic Inflammatory Diseases - Human
Study to Follow -
DOYLESTOWN, Pa., June 20, 2007 /PRNewswire-FirstCall/ -- Quigley
Pharma, www.QuigleyPharma.com , a wholly
owned subsidiary of The Quigley Corporation announced today that it
has completed a follow-up study to evaluate the impact of QR-443 on...
Resveratrol Studies Suggest Broad Implications for SIRT1 Activation
in Neurodegenerative Diseases of Aging Such as Alzheimer's Disease CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 26, 2007 - Sirtris
Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company
focused on discovering and developing small molecule drugs to treat
diseases of aging, announced today that activation of SIRT1, a
member of the sirtuin family of enzymes, was...
Protox Announces Publication in Journal of the National Cancer
Institute Supporting PRX302 as Treatment for Prostatic Diseases Additional data to be published in an upcoming issue of
VANCOUVER, March 20 /CNW/ - Protox(TM) Therapeutics Inc.
(TSX-V:PRX) today announced that two peer-reviewed publications
will feature Protox's PRX 302. The Journal of the National Cancer
Institute ("JNCI") has published th...
Scientists Implicate Gene in Vitiligo and Other Autoimmune Diseases BETHESDA, Md., April 10, 2007--In a study appearing in the March
22 New England Journal of Medicine, scientists supported by the
National Institutes of Healths National Institute of Arthritis and
Musculoskeletal and Skin Diseases (NIAMS) have discovered a
connection between a specific gene and the...
MedImmune Publishes New Data in Nature Immunology Demonstrating The
Role HMGB1 May Play in Systemic Autoimmune Diseases - Preclinical Data Support Rationale for Targeting Pro-Inflammatory
GAITHERSBURG, Md., April 18, 2007 /PRNewswire-FirstCall/ --
MedImmune, Inc. today announced the publication of preclinical
study data demonstrating a role for high mobility group box
protein-1 (HMGB1), a nuclear DNA-bind...
Positive Clinical Data on CC-10004 Confirms Potential as Novel Oral
Approach to Treating Inflammatory Diseases Celgene to Advance Clinical and Regulatory Development of Oral
SUMMIT, N.J., May 22, 2007 /PRNewswire-FirstCall/ -- Celgene
Corporation announced its plans to advance the development of
leading oral anti-inflammatory candidates across a broad range of
Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009... drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular, metabolic and severe neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are...
NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone... 2009.
Novavax, Inc. is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like particle (VLP) technology. The company produces these VLP-based, potent, recombinant...